The KDM5B Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population lacking functional KDM5B histone demethylase activity. This heterogeneous pool provides a versatile model for studying KDM5B loss-of-function in lung adenocarcinoma. Generated via CRISPR/Cas9 gene disruption, the polyclonal mixture avoids clonal bias and supports robust downstream analyses, including epigenetic regulation, chromatin dynamics, and tumor suppressor reactivation studies.
The A-549 cell line is an established model of non-small cell lung cancer derived from a 58-year-old Caucasian male. These adherent epithelial cells carry a KRAS G12S mutation and wild-type p53, representative of pulmonary adenocarcinoma genetics. Widely used for oncogenic signaling, drug response, and epithelial plasticity studies, A-549 cells provide a relevant background for investigating lung cancer pathogenesis and targeted therapies.
KDM5B (JARID1B) is a histone lysine demethylase that removes H3K4me2/me3 activating marks, acting as a transcriptional repressor of tumor suppressor and differentiation genes. It is regulated by upstream factors such as MYC, E2F1, RAR, and HIF1A, and interacts with co-repressors HDAC1/2, SIN3A, SUZ12, and REST. Key downstream targets include CDKN1A (p21), PTEN, BRCA1, and the HOXA gene cluster, linking chromatin remodeling to cell cycle control and stem cell maintenance.
In the A-549 lung adenocarcinoma context, CRISPR/Cas9-mediated disruption of KDM5B is predicted to elevate H3K4 methylation levels at promoter regions of its target genes, leading to their transcriptional de-repression. Reactivation of CDKN1A and PTEN, along with members of the HOX clusters, can impair cell proliferation, induce differentiation, and enhance sensitivity to genotoxic or targeted agents. The polyclonal knockout population thus recapitulates a loss-of-function scenario that is particularly relevant for studying epigenetic dysregulation in non-small cell lung cancer and for exploring synthetic lethal interactions or combination therapies, such as with HDAC inhibitors.
This product is suited for a wide range of epigenetic oncology applications. Researchers can employ ChIP-qPCR to map H3K4me3 changes at target loci, RNA sequencing for transcriptome profiling, and functional assays such as MTT proliferation, colony formation, and wound healing migration. Flow cytometry enables cell cycle analysis, while the polyclonal nature makes it ideal for KDM5B inhibitor screening, cancer stem cell biology, and combination therapy studies with HDAC inhibitors. For further technical details and ordering information, please contact Ascent Research.
